ASSET PURCHASE AGREEMENT BY AND AMONG AVIGEN, INC., BAXTER HEALTHCARE CORPORATION, BAXTER INTERNATIONAL INC., AND BAXTER HEALTHCARE S.A. DECEMBER 17, 2008Asset Purchase Agreement • March 16th, 2009 • Avigen Inc \De • In vitro & in vivo diagnostic substances • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of this 17th day of December, 2008 (the “Effective Date”), by and among Avigen, Inc., a Delaware corporation (“Seller”), and Baxter Healthcare Corporation, a Delaware corporation (“BHC”), Baxter International Inc., a Delaware corporation (“BII”), and Baxter Healthcare S.A., a Swiss Corporation (“BHSA”). BHC, BII and BHSA are individually and collectively referred to herein as “Buyer”.
AMENDMENTPatent and Know-How License, Development and Commercialization Agreement • March 16th, 2009 • Avigen Inc \De • In vitro & in vivo diagnostic substances
This AMENDMENT (the “Amendment”) is entered into as of and to have effect July 22, 2008 (the “Amendment Effective Date”), by and between SDI Diagnostics International Ltd, a limited liability company organized under the laws of Switzerland with offices at Baarerstrasse 96/PF 2252 CH-6302 Zug, Switzerland (“SDI”), and Avigen, Inc., a Delaware corporation with offices at 1301 Harbor Bay Parkway, Alameda, California 94502, USA (“Avigen”).
